Jun 03,2024 TOP STORY

Massive Bio partners with Mika Health to expand oncology app

Massive Bio has partnered with Mika Health by Fosanis to expand access to Mika's digital oncology platform, aiming to provide psycho-oncology services, biomarker testing, and clinical trials to more patients. Through the partnership, patients will receive free access to Mika Health's software addressing oncology-related fatigue, anxiety, and depression, along with access to treatments and testing via Massive Bio's platform. Patients using Mika's app can opt into Massive Bio's AI-enabled clinical trial matching and biomarker testing eligibility engine. The collaboration aims to enhance cancer patient outcomes and experiences by bridging gaps in mental and physical healthcare during treatment.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 03,2024

Massive Bio and Un Ensayo Para Mi Partner to Transform Oncology Clinical Trial Access and Deploy AI Technologies Across LATAM

Massive Bio and Un Ensayo Para Mi have joined forces to expand access to oncology clinical trials across nine LATAM countries. Leveraging Massive Bio's AI-driven technology and UEPM's extensive network, the partnership aims to streamline the clinical trial enrollment process and improve patient care in Latin America. By integrating Massive Bio's solutions, UEPM will enhance the accuracy and efficiency of clinical trial matching, ultimately advancing cancer research and treatment outcomes in the region.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jun 04,2024 TOP STORY

Jasper Health Expands its Reimbursable Cancer Supportive Services to 27 States, Advancing Biden Cancer Moonshot Vision

Jasper Health, a leading provider of human and AI-enabled supportive cancer care, has expanded its 1:1 virtual care services to 27 states across the U.S. This growth aligns with the company's shift towards a new reimbursable business model, prompted by the acceptance of Principal Illness Navigation (PIN) codes by Medicare, Medicaid, and major commercial payers. The expansion enables Jasper to serve patients covered by these payers, including Aetna, Elevance, and UnitedHealthcare.

PRODUCT

#virtual care

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Feb 13,2024

Biofourmis Secures Four New Agreements with Top-20 Pharma on Strength of Platform for Digital Clinical Trials and Digital Biomarkers

Biofourmis has secured four new agreements with top-20 pharmaceutical companies to enhance digital clinical trials and digital biomarker development, particularly in oncology. These partnerships focus on developing digital biomarkers and safety monitoring algorithms for conditions like cytokine release syndrome (CRS). Biofourmis' platform, which supports remote data collection and patient monitoring, aims to reduce study timelines and improve trial efficiency.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
May 28,2024 TOP STORY

Sidekick Health presents impactful real-world data from their digital oncology program at ASCO 2024

Sidekick Health will present real-world data from its digital oncology program at ASCO 2024 on June 1st. This app-based program supports cancer patients in self-managing their health, focusing on mental resilience, nutrition, stress, medication reminders, and symptom tracking. Key findings from a retrospective analysis of the program showed significant improvements in quality of life and symptom severity for highly engaged users. Statistically significant enhancements in energy, sleep, and reductions in fatigue and nausea were observed. Additionally, each week in the program correlated with a 3.5% decrease in overall symptoms, including stress and nausea. The program, offered free to US-based cancer patients, demonstrated that digital self-management can effectively improve patient outcomes.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
May 23,2024

Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395

Owkin announced a drug pipeline in oncology and immunology following a global licensing deal with Idorsia to develop and commercialize OKN4395, a dual inhibitor of prostanoid receptors EP2 and EP4. Owkin leverages its AI engines and multimodal patient data to create detailed biological signatures and identify optimal clinical trial conditions. OKN4395, developed over ten years by Idorsia, is expected to be a best-in-class inhibitor targeting complex cancer pathways.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 14,2024

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

Incyte announced that several abstracts featuring data from its oncology portfolio will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held May 31 – June 4 in Chicago, and at the European Hematology Association 2024 (EHA2024) Congress held on June 13-16 in Madrid, Spain, and virtually.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 07,2024

Researchers Use Foundation Models to Discover New Cancer Imaging Biomarkers

Researchers at Mass General Brigham have utilized foundation models, similar to those powering tools like ChatGPT, to uncover new cancer imaging biomarkers. These biomarkers could revolutionize the identification of patterns in radiological images, leading to advancements in early cancer detection and treatment. Their foundation model, trained on a vast dataset of abnormal radiologic scans, successfully predicted anatomical site, malignancy, and prognosis across various use cases and cohorts. Notably, the model's effectiveness persisted even in scenarios with limited data availability, outperforming existing methods in specialized tasks. Published in Nature Machine Intelligence, the study highlights the potential for more accurate and efficient investigations in image biomarker research.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 09,2024 TOP STORY

Evolent and Careology form strategic care navigation partnership to enhance cancer care in the U.S.

Evolent Health, Inc. has partnered with Careology, a digital cancer care platform, to enhance cancer care experiences for patients in the U.S. This collaboration integrates Careology's patient-focused digital solution with Evolent's care navigation services, aiming to provide personalized and connected support for cancer patients. The platform will empower patients to understand their diagnoses, manage treatments, and monitor symptoms effectively. By leveraging data-driven insights, the partnership aims to identify patients who would benefit from personalized navigation services, potentially reducing emergency visits and costs associated with cancer care. The integrated platform is set to launch by the end of 2024, with a national rollout planned for 2025. As part of the collaboration, Evolent's president, Dan McCarthy, will join the Careology board.

COLLABORATION PARTNERSHIP

#institution

#platform

View Analyst & Ambassador Comments
Go to original news
May 07,2024 TOP STORY

Geisinger Health Plan and OncoHealth to provide comprehensive cancer support to members

Geisinger Health Plan (GHP) with OncoHealth will provide supportive cancer care services to GHP’s more than 550,000 members. GHP will implement OncoHealth’s software and services platform, which combines oncology value management services with virtual cancer care to be sure people with cancer get the most appropriate treatment and support throughout the duration of their treatment. Services include 24/7 oncology nursing, mental health, nutrition, and resource navigation. GHP will begin rolling out OncoHealth in May 2024.

COLLABORATION PARTNERSHIP

#insurance

#virtual care

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY